Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19
暂无分享，去创建一个
D. Covas | G. D. De Santis | J. Bordin | J. F. Marques | A. Mendrone | D. Langhi | C. Dinardo | A. Fabron | M. Rugani | E. A. Ubiali | A. Cortez
[1] Patrick W. Johnson,et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 , 2021, The New England journal of medicine.
[2] F. Polack,et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.
[3] D. Follmann,et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.
[4] D. Araujo,et al. Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing , 2020, medRxiv.
[5] N. Paran,et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma , 2020, EClinicalMedicine.
[6] P. Bieniasz,et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents , 2020, medRxiv.
[7] Patrick W. Johnson,et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. , 2020, The Journal of clinical investigation.
[8] Arturo Casadevall,et al. The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.